<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220123053808N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-09-11</date_registration>
      <primary_sponsor>University of Lorestan</primary_sponsor>
      <public_title>The effect of extracranial direct current stimulation, schema therapy on vaginismus</public_title>
      <acronym></acronym>
      <scientific_title>Compare effectiveness of transcranial direct current stimulation (Tdcs), schema therapy and combination therapy on anxiety, sexual pain and executive functions in women with vaginismus</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-07-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/61522</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The statistical sample will include 60 female patients suffering from vaginismus disorder who will be selected from the statistical population as available sampling. In order to randomly assign the subjects in experimental and control groups, as well as to avoid wasting time until the number of sample people is completely completed, the method of random blocks of 8 will be used. The size of all blocks is equal and in each block there are 2 people in the first intervention group (group A), 2 people in the second intervention group (group B), 2 people in the third intervention group (group C) and 2 people in the control group (group D) will be placed randomly. The randomization tool will be the Random Allocation software. In this way, the output of the software includes different modes of AABBCCDD random order, for each of the blocks, a different order is applied to assign the participants to the study groups. In this process, the order of participants based on blocks cannot be predicted.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Vaginismus.</hc_freetext>
      <i_freetext>Intervention 1: The first intervention group: providing transcranial electrical stimulation of the brain using direct current (tDCS) in the form of ten 20-minute sessions with an intensity of two milliamps and anodic electrical stimulation of the frontal cortex of the left hemisphere (f3) and the cathode in the right prefrontal cortex (fp2) will be placed with an intensity of 2 milliamps. In general, the treatment sessions will be held once a day for three weeks. Intervention 2: The second intervention group: The treatment scheme is a treatment method based on Yang's scheme, which is implemented on clients with vaginismus disorder. This treatment process is carried out during eight treatment sessions in the form of two sessions of one and a half hours each week. Intervention 3: The third intervention group: combining two treatment protocols: protocol one: providing transcranial electrical stimulation of the brain using direct current (tDCS) in the form of ten 20-minute sessions with an intensity of two milliamps and anodic electrical stimulation of the frontal cortex area of ​​the left hemisphere (f3) And the cathode will be placed in the right prefrontal cortex (fp2) with an intensity of 2 milliamps. In general, the treatment sessions will be held once a day for three weeks. Protocol two: The treatment scheme is a treatment method based on Yang's scheme, which will be used on clients with vaginismus disorder. This therapeutic process will be implemented during eight therapeutic sessions in the form of two sessions of one and a half hours each week. Intervention 4: The fourth intervention group: the control group that receives sham stimulation.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data is potentially shareable after de-identifying individuals

When:
The access period starts 6 months after the results are published

To whom:
The data will be available only to researchers working in academic and scientific institutions

Conditions:
Regression analysis is allowed on the delivered data

Where to obtain:
Motahera Nosratabadi 
email
 nosratabadi.mo@fh.lu.ac.ir

How to obtain:
By writing a formal request and the reason for needing access to the data and writing a little bit of your research resume

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>motahareh nosratabadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Khorram abad</address>
        <city>Khorram abad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6815144316</zip>
        <telephone>+98 921 076 1741</telephone>
        <email>motinosi1367@gmail.com</email>
        <affiliation>the university of lorestan</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Motahareh Nosratabadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Lorestan Province - Khorramabad City - 5 km of Tehran Road - Lorestan University Central Organization</address>
        <city>khorram abad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>68151-44316</zip>
        <telephone>+98 66 3312 0661</telephone>
        <email>motinosi1367@gmail.com</email>
        <affiliation>the university of lorestan</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>All women diagnosed with vaginismus disorder who have at least a diploma.                                                                                          All women diagnosed with vaginismus disorder who do not have psychotic symptoms.                                                                        All women diagnosed with vaginismus disorder who do not have substance abuse and psychological disorders (as diagnosed by a psychiatrist or psychologist).                                                            All women diagnosed with vaginismus disorder who do not have gynecological diseases (such as infection).                                    All women diagnosed with vaginismus disorder who have been married for at least 1 to 3 years.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>50 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>All women who have any disorder except vaginismus disorder.
All women who have symptoms similar to vaginismus but do not have a Gynecologist diagnosis.
All women who are not married or have been married for less than a year.
All women who are under 18 years old and over 50 years old.
All women who have symptoms of psychosis and take nerve medication.
All women whose educational qualification is below diploma.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N94.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Vaginismus</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The first intervention group: providing transcranial electrical stimulation of the brain using direct current (tDCS) in the form of ten 20-minute sessions with an intensity of two milliamps and anodic electrical stimulation of the frontal cortex of the left hemisphere (f3) and the cathode in the right prefrontal cortex (fp2) will be placed with an intensity of 2 milliamps. In general, the treatment sessions will be held once a day for three weeks.</i_keyword>
      <i_keyword>The second intervention group: The treatment scheme is a treatment method based on Yang's scheme, which is implemented on clients with vaginismus disorder. This treatment process is carried out during eight treatment sessions in the form of two sessions of one and a half hours each week.</i_keyword>
      <i_keyword>The third intervention group: combining two treatment protocols: protocol one: providing transcranial electrical stimulation of the brain using direct current (tDCS) in the form of ten 20-minute sessions with an intensity of two milliamps and anodic electrical stimulation of the frontal cortex area of ​​the left hemisphere (f3) And the cathode will be placed in the right prefrontal cortex (fp2) with an intensity of 2 milliamps. In general, the treatment sessions will be held once a day for three weeks. Protocol two: The treatment scheme is a treatment method based on Yang's scheme, which will be used on clients with vaginismus disorder. This therapeutic process will be implemented during eight therapeutic sessions in the form of two sessions of one and a half hours each week.</i_keyword>
      <i_keyword>The fourth intervention group: the control group that receives sham stimulation.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Primary outcome: sexual pain score. Timepoint: 1 to 5 days before the intervention and 1 to 5 days after the intervention. Method of measurement: McGill pain questionnaire.</prim_outcome>
      <prim_outcome>Secondary outcome: anxiety score. Timepoint: 1 to 5 days before the intervention and 1 to 5 days after the intervention. Method of measurement: Kettle Anxiety Questionnaire.</prim_outcome>
      <prim_outcome>Individual's executive performance scores. Timepoint: 1 to 5 days before the intervention and 1 to 5 days after the intervention. Method of measurement: Nback memory test, Wisconsin test, Semantic Stroop test.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Sexual pain score. Timepoint: Before intervention and after intervention. Method of measurement: McGill Sexual Pain Questionnaire 22 questions.</sec_outcome>
      <sec_outcome>Anxiety. Timepoint: Before intervention and after intervention. Method of measurement: Kettle Anxiety Questionnaire 40 questions.</sec_outcome>
      <sec_outcome>Executive functions. Timepoint: Before intervention and after intervention. Method of measurement: Semantic Strope, NB Memory Test, Wisconsin Test.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>University of Lorestan</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-07-27</approval_date>
        <contact_name>Ethics committee of Lorestan University of Medical Sciences</contact_name>
        <contact_address>Moalem St., Shahid Anoushirvan Rezaei Square, University of Medical Sciences Khorram abad Lorestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
